Larger gene panels are the predominant NGS testing strategy in EU5

Article tags Centralised Diagnostics (CEDx)In-vitro diagnosticsMolecular Diagnostics (MDx)Next Generation Sequencing (NGS)Tissue Diagnostics (TDx)EuropeIVD GatewayLabPRO PlusMolecular Diagnostics (MDx)Next Generation Sequencing (NGS)Tissue Diagnostics (TDx)

The growing number of biomarkers for which oncologists need information for treatment decision-making has necessitated a shift toward more comprehensive genomic profiling through next-generation sequencing (NGS).

Mid-large NGS panel testing for more than 20 genes is the most commonly used oncology testing strategy.

The European Society for Medical Oncology (ESMO) acknowledges that large multigene panels could be used for cancers such as advanced non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma, for which it recommends the routine use of NGS testing, if the additional cost compared with small panels is within an acceptable range.

For more on the NGS cancer biomarker testing trends, download the white paper on Next-generation sequencing (NGS) in cancer biomarker testing: Testing trends in European molecular and pathology laboratories

Mon, 20th Jun 2022 Article tags Centralised Diagnostics (CEDx)In-vitro diagnosticsMolecular Diagnostics (MDx)Next Generation Sequencing (NGS)Tissue Diagnostics (TDx)EuropeIVD GatewayLabPRO PlusMolecular Diagnostics (MDx)Next Generation Sequencing (NGS)Tissue Diagnostics (TDx)